These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26925841)

  • 41. PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.
    Brunen D; de Vries RC; Lieftink C; Beijersbergen RL; Bernards R
    Mol Cancer Ther; 2018 Apr; 17(4):849-857. PubMed ID: 29440296
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neurofibromatosis type 1 alternative splicing is a key regulator of Ras/ERK signaling and learning behaviors in mice.
    Nguyen HT; Hinman MN; Guo X; Sharma A; Arakawa H; Luo G; Lou H
    Hum Mol Genet; 2017 Oct; 26(19):3797-3807. PubMed ID: 28934393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
    Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.
    Xiao Z; Ding N; Xiao G; Wang S; Wu Y; Tang L
    Anat Rec (Hoboken); 2012 Dec; 295(12):2122-8. PubMed ID: 22907845
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
    Berlak M; Tucker E; Dorel M; Winkler A; McGearey A; Rodriguez-Fos E; da Costa BM; Barker K; Fyle E; Calton E; Eising S; Ober K; Hughes D; Koutroumanidou E; Carter P; Stankunaite R; Proszek P; Jain N; Rosswog C; Dorado-Garcia H; Molenaar JJ; Hubank M; Barone G; Anderson J; Lang P; Deubzer HE; Künkele A; Fischer M; Eggert A; Kloft C; Henssen AG; Boettcher M; Hertwig F; Blüthgen N; Chesler L; Schulte JH
    Mol Cancer; 2022 Jun; 21(1):126. PubMed ID: 35689207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. JNK inhibitors increase osteogenesis in Nf1-deficient cells.
    Sullivan K; El-Hoss J; Little DG; Schindeler A
    Bone; 2011 Dec; 49(6):1311-6. PubMed ID: 21964323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
    Morris EJ; Jha S; Restaino CR; Dayananth P; Zhu H; Cooper A; Carr D; Deng Y; Jin W; Black S; Long B; Liu J; Dinunzio E; Windsor W; Zhang R; Zhao S; Angagaw MH; Pinheiro EM; Desai J; Xiao L; Shipps G; Hruza A; Wang J; Kelly J; Paliwal S; Gao X; Babu BS; Zhu L; Daublain P; Zhang L; Lutterbach BA; Pelletier MR; Philippar U; Siliphaivanh P; Witter D; Kirschmeier P; Bishop WR; Hicklin D; Gilliland DG; Jayaraman L; Zawel L; Fawell S; Samatar AA
    Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R; Piperdi S; Gorlick R
    Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.
    Wang H; Daouti S; Li WH; Wen Y; Rizzo C; Higgins B; Packman K; Rosen N; Boylan JF; Heimbrook D; Niu H
    Cancer Res; 2011 Aug; 71(16):5535-45. PubMed ID: 21705440
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MEKK2 mediates aberrant ERK activation in neurofibromatosis type I.
    Bok S; Shin DY; Yallowitz AR; Eiseman M; Cung M; Xu R; Li N; Sun J; Williams AL; Scott JE; Su B; Shim JH; Greenblatt MB
    Nat Commun; 2020 Nov; 11(1):5704. PubMed ID: 33177525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.
    Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
    Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction of mitotic catastrophe by PKC inhibition in Nf1-deficient cells.
    Zhou X; Kim SH; Shen L; Lee HJ; Chen C
    Cell Cycle; 2014; 13(15):2340-8. PubMed ID: 25483185
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
    Marampon F; Ciccarelli C; Zani BM
    Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.
    Finn RS; Ahn DH; Javle MM; Tan BR; Weekes CD; Bendell JC; Patnaik A; Khan GN; Laheru D; Chavira R; Christy-Bittel J; Barrett E; Sawyer MB; Bekaii-Saab TS
    Invest New Drugs; 2018 Dec; 36(6):1037-1043. PubMed ID: 29785570
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance.
    Tak E; Kim M; Cho Y; Choi S; Kim J; Han B; Kim HD; Jang CS; Kim JE; Hong YS; Kim SY; Kim TW
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34779495
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
    Wen-Sheng W
    Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma].
    Wang Y; Yang J; Gao Y; Zhao XL; Li HZ; Yao Z
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):522-8. PubMed ID: 19957553
    [TBL] [Abstract][Full Text] [Related]  

  • 60. VEGFR, RET, and RAF/MEK/ERK pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment.
    Mei J; Zhu X; Wang Z; Wang Z
    Cell Biochem Biophys; 2014 May; 69(1):151-6. PubMed ID: 24375110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.